Skip to main
ANGO
ANGO logo

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics has demonstrated strong financial performance in F2Q25, with all product lines in the Med Tech segment reporting impressive growth, including notable increases for Auryon (21.8%), AngioVac (50.7%), and AlphaVac (33.3%). The recent FDA clearance of the NanoKnife System for prostate tissue ablation positions the company for potential expansion in the Med Tech market, utilizing its innovative irreversible electroporation technology that offers a minimally invasive treatment option. This positive momentum, bolstered by increased FY25 adjusted EBITDA guidance and the anticipated favorable results from ongoing clinical trials, underscores AngioDynamics's strengthening market position and growth potential.

Bears say

AngioDynamics Inc. faces several significant risks that contribute to a negative outlook, including lower-than-expected growth in Med Tech revenue and potential divestiture of Med Device products, which have already shown a notable decline in sales. The company reported an adjusted net loss of $1.7 million as well as a pro forma year-over-year decline in actual sales, indicating challenges in maintaining profitability despite a modest growth in net sales. Furthermore, competition is increasing, and concerns regarding potential dilution risk add to the uncertainty surrounding the company's financial stability and future performance.

AngioDynamics (ANGO) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Buy based on their latest research and market trends.

According to 8 analysts, AngioDynamics (ANGO) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.